Onco360 Oncology Pharmacy’s Post

The FDA has approved #Fruzaqla, a new pill for adults with advanced colorectal cancer that has spread, designed to block the tumor's blood supply and taken once daily. Another approved option is #LONSURF, an oral chemotherapy, combined with #Avastin, an IV drug, for those previously treated with specific cancer therapies, shown to extend life and delay cancer progression. This is something to talk about. Join 1000s of #colorectalcancer patients and continue the conversation today: https://lnkd.in/g3uEc-R9

Our recent CASES report provides strategic insights into advanced cervical cancer treatment practices across the Midwest. The report covers frontline and second-line therapy trends, biomarker-driven approaches, and expert perspectives from top oncologists. Peek inside this report! https://lnkd.in/ejzGrKmm #OncologyInsights #Pharma #CancerCare

🚀 Stay ahead in oncology with the latest FDA approvals and upcoming PDUFA dates! Unlock actionable insights and real-time market intelligence with LARVOL PULSE—your trusted platform for tracking regulatory trends in cancer research. 📚 Catch up on past FDA oncology approvals: https://bit.ly/4fW9KWv #LARVOL #CancerResearch #FDA #PDUFA #LARVOLPULSE #OncologyInsights

Stay ahead in oncology with the latest FDA approvals and upcoming PDUFA dates! Discover valuable insights and real-time market intelligence with LARVOL PULSE—your go-to platform for tracking regulatory trends in cancer research. Catch up on past FDA oncology approvals here: https://bit.ly/3Oc6zhl #LARVOL #CancerResearch #FDAApprovals #PDUFA #LARVOLPULSE #OncologyInsights #RealTimeUpdates

Merck has announced the Discontinuation of KeyVibe and KEYFORM Programs Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has discontinued its KeyVibe and KEYFORM programs. Phase 3 trials evaluating combinations of pembrolizumab (KEYTRUDA®) with vibostolimab and favezelimab failed to meet survival goals. Enrollment in these studies has been halted, and patients in ongoing trials may continue treatment until study completion. https://lnkd.in/daUuNwpY Marjorie Green #Cancer #CancerResearch #KeyVibe #KEYFORM #CancerTreatment #Merck #CancerDrug #Medicine #Health #Oncology #OncoDaily

When a patient is diagnosed with cancer it is often the start of a complex and challenging journey. Evernorth Oncology Benefit Services was designed to meet the needs of patients and plan sponsors through every stage of care in a single experience. Learn how we are transforming oncology care through a holistic, patient-centric, and consultative approach: https://bit.ly/3YfmgJt

✍️ Must Read this amazing article about the 7 Ways Oncology Pharmacists Impact #Cancer Care 1. Drug interactions 2. Comorbid conditions 3. Baseline organ dysfunction 4. Tolerability of previous cycles 5. Pharmacogenomics 6. Patient weight 7. Under/ over-dosing implications https://lnkd.in/dZYWHPqu

✍️ Must Read this amazing article about the 7 Ways Oncology Pharmacists Impact #Cancer Care 1. Drug interactions 2. Comorbid conditions 3. Baseline organ dysfunction 4. Tolerability of previous cycles 5. Pharmacogenomics 6. Patient weight 7. Under/ over-dosing implications https://lnkd.in/dVjPWTpK

✍️ Must Read this amazing article about the 7 Ways Oncology Pharmacists Impact #Cancer Care 1. Drug interactions 2. Comorbid conditions 3. Baseline organ dysfunction 4. Tolerability of previous cycles 5. Pharmacogenomics 6. Patient weight 7. Under/ over-dosing implications https://lnkd.in/dVjPWTpK

Through our innovative oncology research, we are evaluating subcutaneous immunotherapy formulations that we hope will reduce treatment times and improve the quality of care for patients. We are inspired by the work that has been done to improve outcomes for patients living with #kidneycancer. Learn more about subcutaneous immunotherapy: https://bit.ly/45v7wt7 #WorldKidneyCancerDay